ArticleApplied biochemistry and biotechnology2026
Anti-Inflammatory Role of Exopolysaccharides in Osteoarthritis via Modulation of Redox and Inflammatory/Catabolic Signaling Networks.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a leading cause of disability worldwide, characterized by progressive cartilage degradation, chronic inflammation, and joint structural deterioration. Beyond its physical burden, OA significantly impacts psychological well-being and socioeconomic stability. Current pharmacological treatments, such as meloxicam (Mel), provide symptomatic relief but fail to comprehensively address the inflammatory mechanisms driving OA progression while also posing risks like liver toxicity. The study was designed to test whether exopolysaccharide (EPS) improves cartilage structural integrity in a ciprofloxacin (CIP)-induced OA-like experimental arthropathy, with inflammatory, oxidative, and signaling markers serving as supportive mechanistic outcomes. The EPS-producing Bacillus altitudinis strain BAE2023 was identified via 16S rRNA sequencing, with EPS composition confirmed through GC/MS and FTIR analyses. Forty male albino rats were divided into five groups: control, CIP-induced OA-like experimental arthropathy, and treatment groups receiving EPS, Mel, or their combination. Results demonstrated that combined EPS and Mel therapy significantly improved joint structural parameters, improved the measured redox profile by increasing SOD, GST, and GSH and by lowering MDA, a marker of lipid peroxidation, and suppressed key circulating inflammatory mediators. Gene expression analysis revealed that EPS successfully modulated the Nrf2/Ho-1 and Cox-2/Mmp1a signaling axes, highlighting its role in inflammation resolution and joint repair. Histopathological evaluation further confirmed cartilage regeneration and reduced hepatic toxicity. By effectively modulating inflammation and oxidative stress, EPS emerges as a promising therapeutic strategy for managing disability-related OA. This study underscores the potential of EPS in enhancing joint health, minimizing medication-induced toxicity, and improving overall quality of life for individuals suffering from OA. Integrating EPS into OA treatment paradigms may offer a more holistic, a chondroprotective and structure-preserving effect to disability management.
Indexed as
Identifiers
42742926What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.